dacomitinib beats iressa as first line treatment for egfr mutation-positive nsclc
Published 7 years ago • 485 plays • Length 7:59Download video MP4
Download video MP3
Similar videos
-
7:53
improved progression-free survival with iressa as adjuvant therapy
-
1:26
first line treatment of egfr mutation-positive nsclc
-
4:02
treatment of egfr mutated nsclc - 2022 program: targeted therapies forum - english
-
7:05
is dacomitinib survival benefit enough to make it a contender as first line treatment? (bmic-044)
-
2:30
acquired resistance to osimertinib in egfr nsclc - 2022 program: targeted therapies forum - english
-
4:26
combinations and other options for acquired resistance in egfr mutation-positive nsclc
-
1:01
dr. philip bonomi: gefitinib and later generations of egfr inhibitors
-
6:06
the adaura trial: the effect on egfr treatment - targeted therapies in lung cancer 2023
-
3:35
grace targeted therapies lung cancer 2021 - current treatment options for egfr fusions e.g. rad 51
-
18:44
2020 ttf egfr breakout piotrowska part 2 - current options upon acquired resistance to osimertinib
-
3:28
should third generation egfr inhibitors be used before or after progression?
-
11:23
2020 ttf egfr breakout piotrowska part 1 - current options upon acquired resistance to osimertinib
-
14:43
gracecast-070_lung-cancer_q&a for acquired egfr tki and re-biopsying
-
9:28
asco 2021 lung: amivantamab lazertinib in egfr, patritumab deruxtecan in egfr acquired resistance
-
2:44
grace targeted therapies lung cancer 2021 -progression on tagrisso, amivantamab or better treatment?
-
5:07
q&a: what is the efficacy of amivantamab and lazertinib? - targeted therapies in lung cancer 2023
-
5:54
key points from the adaura trial: osimertinib - targeted therapies in lung cancer 2023
-
16:48
2020 ttf egfr breakout - weiss choice of frontline egfr therapies
-
2:21
should egfr tki therapy be continued beyond progression?